Long-Acting HIV Prevention Now Available in France
A latest, long-acting injectable form of HIV prevention, known as Apretude (cabotegravir), is now available in France, offering a new option for individuals at risk of contracting the virus. This marks the first time such a preventative treatment has been offered in an injectable format.
Apretude is designed for HIV-1 negative adults and adolescents weighing at least 77 pounds. The treatment provides an alternative to daily oral PrEP (pre-exposure prophylaxis) pills, potentially improving adherence and convenience for those who could benefit from HIV prevention.
The arrival of cabotegravir in France has been anticipated for some time, with health officials and advocates recognizing the potential to expand access to PrEP and reduce new HIV infections. The injectable form of PrEP could be particularly beneficial for individuals who find it difficult to take a daily pill, or who prefer a more discreet method of prevention.
Apretude is administered as an injection, with an initial regimen followed by maintenance injections given every two months. More information about Apretude, including prescribing information and a boxed warning, can be found at the official Apretude website.
This development represents a significant step forward in the fight against HIV, offering a new tool to help individuals protect themselves and contribute to ending the HIV epidemic. The availability of Apretude in France follows its approval and rollout in other regions and underscores the ongoing commitment to innovative HIV prevention strategies.
